Symlin (pramlintide acetate) Injection
Approved: March 16, 2005 Company: Amylin Pharmaceuticals, Inc.
Treatment for:
Diabetes in conjunction with
insulin Symlin is a synthetic analog of human amylin, a naturally occurring hormone that is made in the beta cells of the pancreas. Symlin is used in conjunction with insulin to control glucose in patients with type 2 diabetes who use insulin, and in patients with type 1 diabetes.
Back to
Latest FDA Approvals 
FDA Approves Symlin 
Linear Mode
